Tag: articles

NEXITY
Société anonyme
au capital de 280 648 620 euros
Siège Social : 67 rue Arago
93400 Saint-Ouen-sur-Seine
444 346 795 RCS Bobigny

NEXITY
Société anonyme
au capital de 280 648 620 euros
Siège Social : 67 rue Arago
93400 Saint-Ouen-sur-Seine
444 346 795 RCS Bobigny

At the initiative and by the decision of the Board of AUGA group, RAB (code 126264360, address Konstitucijos ave. 21C, Vilnius, the “Company”), it has been decided to revoke the extraordinary General Meeting of Shareholders convened on July 14, 2025, following the decision of the Vilnius Regional Court to extend the deadline for submitting the Company's restructuring plan for Court approval until August 19, 2025. This Court decision was based on unresolved issues regarding the contested creditor claims in the Company's restructuring case, which currently prevent the creditors from making decisions in accordance with the Law on Legal Entities' Insolvency (hereinafter referred to as the "Insolvency Law").

SANTA MONICA, CA, June 30, 2025 (GLOBE NEWSWIRE) -- Oliveda International, Inc. (OTC Pink: OLVI) today announced that after a true waterless beauty movement emerged in the United States within just two years, with over 60,000 waterless beauty consultants, and Olive Tree People USA Inc. exploded from 40 to over 10,000 packages per day and up to 4 million in sales per day in 2024 alone, olive farmer and CEO Thomas Lommel has set the course for global expansion by establishing subsidiaries in Canada and Europe.

                                                                                                                  
June 30^th, 2025

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.